Ketamine is presented as an NMDA receptor antagonist with antidepressant relevance and schizophrenia-like effects depending on context. The review emphasizes its temporal dissociation of early positive symptoms and later antidepressant effects.
First-pass extracted concept
ketamine
Candidate: concept label2 source documents8 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
(R)-ketamine, (S)-ketamine
Extracted Explainers
What the tool is doing
Resources required
The abstract does not specify formulation, route, monitoring, or co-interventions. It only notes severe restrictions around its approved use.
Its effects are discussed in relation to dose, route of administration, and exposure time course. Interpretation also requires considering rapid and extensive metabolism.
What problem it solves
In depressive-like status, NMDA receptor blockade is described as potentially leading to symptom amelioration or remission. Ketamine is the named example tied to treatment-resistant depression.
It provides clinically useful effects across anesthesia, analgesia, and depression-related contexts. The review uses it as the benchmark for identifying mechanisms worth preserving in next-generation agents.
What it does not solve
The abstract indicates ketamine does not avoid psychotomimetic liability in all settings. Healthy individuals and schizophrenia patients may instead develop or worsen psychotic symptoms after NMDA antagonist administration.
Ketamine does not avoid important adverse effects, including dissociative, psychotomimetic, cognitive, and peripheral side effects. The review explicitly motivates development of alternatives that retain benefits while limiting these liabilities.
Alternatives
The abstract groups ketamine with PCP and dizocilpine (MK-801) as NMDA antagonists, but does not present them as therapeutic substitutes.
The abstract contrasts ketamine with its metabolites as possible sources of clinically relevant effects. It also distinguishes direct NMDA receptor inhibition from other putative lower-affinity targets.
Evidence Snippets
Supporting Sources
Linked Claims
Ketamine has been recently approved for treatment-resistant depression, although with severe restrictions.
Quoted textsource-backed
However, ketamine has been recently approved for treatment-resistant depression, although with severe restrictions.
NMDA receptor antagonists such as PCP, MK-801, and ketamine have long been considered a model of schizophrenia in animals and humans.
Quoted textsource-backed
N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP), dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia, both in animals and humans.
At similar dosage, positive symptoms of schizophrenia appear before antidepressant effects emerge after NMDA antagonist exposure.
Quoted textsource-backed
Interestingly, the dosage in both conditions is similar, and positive symptoms of schizophrenia appear before antidepressant effects emerge.
Ketamine is associated with dissociative, psychotomimetic, cognitive, and peripheral side effects with short-term or prolonged exposure.
Quoted textsource-backed
Dissociative, psychotomimetic, cognitive, and peripheral side effects associated with short-term or prolonged exposure, as well as recreational ketamine use, are also discussed.
The anesthetic and analgesic properties of ketamine are generally attributed to direct ketamine-induced inhibition of NMDA receptors.
Quoted textsource-backed
Whereas the anesthetic and analgesic properties of ketamine are generally attributed to direct ketamine-induced inhibition of N-methyl-D-aspartate receptors
Beyond NMDA receptors, ketamine has other putative lower-affinity pharmacological targets including GABA, dopamine, serotonin, sigma, opioid, and cholinergic receptors, as well as voltage-gated sodium and HCN channels.
Quoted textsource-backed
other putative lower-affinity pharmacological targets of ketamine include, but are not limited to, γ-amynobutyric acid (GABA), dopamine, serotonin, sigma, opioid, and cholinergic receptors, as well as voltage-gated sodium and hyperpolarization-activated cyclic nucleotide-gated channels.
Ketamine undergoes rapid and extensive metabolism to norketamine, dehydronorketamine, hydroxyketamine, and hydroxynorketamine metabolites.
Quoted textsource-backed
We further describe ketamine's pharmacokinetics, including its rapid and extensive metabolism to norketamine, dehydronorketamine, hydroxyketamine, and hydroxynorketamine (HNK) metabolites.
Ketamine has dissociative anesthetic properties and also exerts analgesic, anti-inflammatory, and antidepressant actions.
Quoted textsource-backed
Although best characterized for its dissociative anesthetic properties, ketamine also exerts analgesic, anti-inflammatory, and antidepressant actions.